Anxiety - Panic Disorders: References

  • Agency for Health Care Policy and Research. Depression in Primary Care: Treatment of Major Depression.Washington DC: US Department of Health and Human Services; 1993.

  • AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Quality and Safety in Health Care. 2003;12:18–23. [PMC free article] [PubMed]

  • Akhondzadeh S, Naghavi HR, Vazirian M, et al. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. Journal of Clinical Pharmacy and Therapeutics.2001;26:363–367. [PubMed]

    This is the reference for study ID .

  • Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder. British Journal of Psychiatry. 2001;179:15–22. [PubMed]

  • Allgulander C, Dahl AA, Austin C, et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder.American Journal of Psychiatry. 2004;161:1624–1649. [PubMed]

  • Allgulander C, Florea I, Huusom AKT. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. International Journal of Neuropsychopharmacology. 2006;9:495–505. [PubMed]

  • Allgulander C, Jorgensen T, Wade A, et al. Health-related quality of life (HRQOL) among patients with generalised anxiety disorder: evaluation conducted alongside an escitalopram relapse prevention trial. Current Medical Research and Opinion. 2007;23:2543–2549. [PubMed]

  • Alonso J, Angermeyer MC, Bernert S, et al. Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica. 2004;109(Suppl. 420):38–46. [PubMed]

  • Alonso J, Angermeyer MC, Bernet S, et al. Prevalence of mental disorders in Europe: results from the European study of the epidemiology of mental disorders (ESEMeD) project. Acta Psychiatrica Scandinavica. 2004;109:21–27. [PubMed]

  • Alvidrez J, Azocar F. Distressed women’s clinic patients: preferences for mental health treatments and perceived obstacles. General Hospital Psychiatry. 1999;21:340–347. [PubMed]

  • Amsterdam JD, Li Y, Soeller I, et al. A randomized, double-blind, placebo-controlled trial of oral matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. Journal of Clinical Psychopharmacology.2009;29:378–382. [PMC free article] [PubMed]

  • Andlin-Sobocki P, Wittchen H-U. Cost of anxiety disorders in Europe. European Journal of Neurology.2005;12(Suppl. 1):39–44. [PubMed]

  • Andlin-Sobocki P, Jönsson B, Wittchen H-U, et al. Cost of disorders of the brain in Europe. European Journal of Neurology. 2005;12(Suppl. 1):1–27. [PubMed]

  • Andreatini R, Sartori VA, Seabra MLV, et al. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled study. Phytotherapy Research. 2002;16:650–654. [PubMed]

  • Andrews G.Tolkein II Team. A Needs-Based, Costed Stepped-Care Model for Mental Health Services. Sydney: Clinical Research Unit for Anxiety and Depression, University of New South Wales; 2006.

  • Andrews G, Issakidis C, Sanderson K, et al. Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. British Journal of Psychiatry. 2004;184:526–533. [PubMed]

  • Ansseau M, Olie JP, von Frenckell R, et al. Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder. Psychopharmacology. 1991;104:439–443.[PubMed]

  • APA. Diagnostic and Statistical Manual of Mental Disorders. 3rd edition. Washington, DC: APA; 1980. (DSM-III)

  • APA. Diagnostic and Statistical Manual of Mental Disorders. 3rd edition –revision. Washington, DC: APA; 1987. (DSM–III-R)

  • APA. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: APA; 1994. (DSM–IV)

  • Arntz A. Cognitive therapy versus applied relaxation as treatment of generalized anxiety disorder. Behaviour Research and Therapy. 2003;41:633–646. [PubMed]

  • Arroll B, Kendrick T. Anxiety. In: Gask L, Lester H, Kendrick T, Peveler R, editors. Primary Care Mental Health.Glasgow: Bell and Bain Ltd; 2009. pp. 147–149.

  • Ashton H. Adverse effects of prolonged benzodiazepine use. Adverse Drug Reaction Bulletin. 1986;118:440–443.

  • AstraZeneca. An international, multi-center, randomized, double-blind, parallel-group, placebo-controlled, active-controlled study of the efficacy and safety of sustained-release quetiapine fumarate (Seroquel SR) in the treatment of generalized anxiety disorder (Silver Study) 2007. Available from ClinicalTrials​.gov (NCT00322595)

  • AstraZeneca. A multicenter, randomized, double-blind, parallel-group, placebo-controlled, active-controlled study of the efficacy and safety of sustained-release quetiapine fumarate (Seroquel) compared with placebo in the treatment of generalized anxiety disorder (Gold Study) 2007. Available from ClinicalTrials​.gov (NCT00329446)

  • AstraZeneca. A multi-center, randomized, parallel-group, placebo-controlled study of the efficacy and safety of sustained-release quetiapine fumarate (Seroquel) compared with placebo in the treatment of generalized anxiety disorder (Titanium study) 2007. Available from ClinicalTrials​.gov (NCT00329264)

  • AstraZeneca. A multi-center, randomized, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate extended-release (Seroquel XR) as monotherapy in the treatment of elderly patients with generalized anxiety disorder (Chromium study) 2008. Available from ClinicalTrials​.gov (NCT00389064)

  • Baldwin DS, Ajel K. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatric Disease and Treatment. 2007;3:185–191. [PMC free article] [PubMed]

  • Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacolgy. 2005;19:567–596. [PubMed]

  • Baldwin DS, Huusom AKT, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. British Journal of Psychiatry. 2006;189:264–272.[PubMed]

  • Ball S, Kuhn A, Wall D, et al. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. Journal of Clinical Psychiatry.2005;66:94–99. [PubMed]

  • Bandelow B, Sievert K, Röthemeyer M, et al. What treatments do patients with panic disorder and agoraphobia get?European Archives of Psychiatry and Clinical Neuroscience. 1995;245:165–171. [PubMed]

  • Barlow DH. Unravelling the mysteries of anxiety and its disorders from the perspective of emotion theory. American Psychologist. 2000;55:1247–1263. [PubMed]

  • Barlow DH, Rapee RM, Brown TA. Behavioral treatment of generalized anxiety disorder. Behavior Therapy.1992;23:551–570.

  • Batelaan N, Smit F, van Balkom T, et al. Societal costs of panic disorder and subthreshold panic disorder. Journal of Affective Disorders. 2007;104:127–136. [PubMed]

  • Baumeister H, Harter M. Prevalence of mental disorders based on general population surveys. Social Psychiatry and Epidemiology. 2007;42:537–546. [PubMed]

  • Beasley CM, Koke SC, Nilsson ME, et al. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clinical Therapeutics. 2000;22:1319–1330.[PubMed]

  • Beck AT, Emery G, Greenberg RL. Anxiety Disorders and Phobias: A Cognitive Perspective. New York: Basic Books; 1985.

  • Becker E, Goodwin R, Holting C, et al. Content of worry in the community: what do people with generalized anxiety disorder or other disorders worry about? Journal of Nervous and Mental Disease. 2003;191:688–691. [PubMed]

  • Bee P, Bower P, Lovell K, et al. Psychotherapy mediated by remote communication technologies: a meta-analytic review. BMC Psychiatry. 2008;8:60. [PMC free article] [PubMed]

  • Berg AL, Sandell R, Sandahl C. Affect-focused body psychotherapy in patients with generalized anxiety disorder: evaluation of an integrative method. Journal of Psychotherapy Integration. 2009;19:67–85.

  • Berlin JA. Does blinding of readers affect the results of meta-analyses? Lancet. 2001;350:185–186. [PubMed]

  • Bielski RJ, Bose A. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalised anxiety disorder. Annals of Clinical Psychiatry. 2005;17:65–69. [PubMed]

  • Bishop SJ, Duncan J, Lawrence JD. State anxiety modulation of the amygdale response to unattended threat-related stimuli. Nature Neuroscience. 2004;7:184–188. [PubMed]

  • Bitran S, Barlow DH, Spiegel DA. Generalized anxiety disorder. In: Gelder MG, Andreasen MG, Lopez-Ibor JJ, Geddes JR, editors. New Oxford Textbook of Psychiatry. New York: Oxford University Press; 2009. pp. 729–739.

  • Bjorner T, Kjolsrod L. How GPs understand patients’ stories: a qualitative study of benzodiazepine and minor opiate prescribing in Norway. European Journal of General Practice. 2002;8:25–30.

  • Blair DT, Ramones VA. The undertreatment of anxiety: overcoming the confusion and stigma. Journal of Psychosocial Nursing and Mental Health Services. 1996;34:9–18. [PubMed]

  • Blazer DG, Hughes D, George LK, et al. Generalized anxiety disorder. In: Robins LN, Regier DA, editors.Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York: The Free Press; 1991.

  • Blenkiron P. Coping with depression: a pilot study to assess the efficacy of a self-help audio cassette. British Journal of General Practice. 2001;51:366–370. [PMC free article] [PubMed]

  • Boardman J, Henshaw C, Willmott S. Needs for mental health treatment among general practice attenders. British Journal of Psychiatry. 2004;185:318–327. [PubMed]

  • Bond AJ, Wingrove J, Curran HV, et al. Treatment of generalised anxiety disorder with a short course of psychological therapy, combined with buspirone or placebo. Journal of Affective Disorders. 2002;72:267–271.[PubMed]

    This is the reference for study ID .

  • Borkovec TD, Costello E. Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. Journal of Consulting and Clinical Psychology. 1993;61:611–619. [PubMed]

  • Borkovec TD, Roemer L. Perceived function of worry among generalized anxiety disorder subjects: distraction from more emotionally distressing topics? Journal of Behavior Therapy and Experimental Psychiatry. 1995;26:25–30.[PubMed]

  • Borkovec TD, Newman MG, Pincus AL, et al. A component analysis of cognitive-behavioral therapy for generalized anxiety disorder and the role of interpersonal problems. Journal of Consulting and Clinical Psychology.2002;70:288–298. [PubMed]

  • Bose A, Korotzer A, Gommoll C, et al. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depression and Anxiety. 2008;25:854–861. [PubMed]

  • Bourin M, Malinge M. Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam.Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1995;19:567–575. [PubMed]

  • Bower P, Gilbody S. Stepped care in psychological therapies: access, effectiveness and efficiency: narrative literature review. The British Journal of Psychiatry. 2005;186:11–17. [PubMed]

  • Bower P, Rowland N, Hardy R. The clinical effectiveness of counselling in primary care: a systematic review and meta-analysis. Psychological Medicine. 2003;33:203–215. [PubMed]

  • Bower P, Gilbody S, Richards D, et al. Collaborative care for depression in primary care: making sense of a complex intervention: systematic review and meta-regression. British Journal of Psychiatry. 2006;189:484–493. [PubMed]

  • Bowman D, Scogin F, Floyd M, et al. Efficacy of self-examination therapy in the treatment of generalized anxiety disorder. Journal of Counselling Psychology. 1997;44:267–273.

  • Brambilla P, Cipriani A, Hotopf M, et al. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and new antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry. 2005;38:69–77. [PubMed]

  • Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. Journal of Clinical Psychiatry. 2005;66:1321–1325. [PubMed]

  • Brawman-Mintzer O, Knapp RG, Rynn M, et al. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry. 2006;67:874–881. [PubMed]

  • Brazier JE, Roberts J. The estimation of a preference based measure of health from the SF-12. Medical Care.2004;42:851–859. [PubMed]

  • Brazier JE, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics. 2002;21:271–292. [PubMed]

  • Breitholtz E, Westling BE, Öst LG. Cognitions in generalized anxiety disorder and panic disorder patients. Journal of Anxiety Disorders. 1998;12:567–577. [PubMed]

  • Briggs A, Sculpher M, Claxton C. Making decision models probabilistic. In: Briggs A, Sculpher M, Claxton C, editors. Decision Modelling for Health Economic Evaluation. New York: Oxford University Press; 2006.

  • British Medical Association & the Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF)Vol. 57. London: Pharmaceutical Press; 2009.

  • British Medical Association & the Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF)Vol. 59. London: Pharmaceutical Press; 2010.

  • Brooks R. with the EuroQol Group. EuroQol: the current state of play. Health Policy. 1996;37:53–72. [PubMed]

  • Brown GW, Harris TO. Aetiology of anxiety and depressive disorders in an inner-city population: 1-Early adversity.Psychological Medicine. 1993;23:143–154. [PubMed]

  • Butler G, Fennell M, Robson P, et al. Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder. Journal of Consulting and Clinical Psychology. 1991;59:167–175.[PubMed]

  • Bystritsky A, Wagner AW, Russo JE, et al. Assessment of beliefs about psychotropic medication and psychotherapy: development of a measure for patients with anxiety disorders. General Hospital Psychiatry. 2005;27:313–318.[PubMed]

  • Bystritsky A, Kerwin L, Niv N, et al. Clinical and subthreshold panic disorder. Depression and Anxiety.2010;27:381–389. [PMC free article] [PubMed]

  • Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. British Medical Journal. 2005;331:897–900. [PMC free article] [PubMed]

  • Carlbring P, Westling BE, Ljungstrand P, et al. Treatment of panic disorder via the internet: a randomised trial of a self-help program. Behavior Therapy. 2001;32:751–764.

  • Carlbring P, Ekselius L, Andersson G. Treatment of panic disorder via the internet: a randomized trial of CBT vs. applied relaxation. Journal of Behavior Therapy and Experimental Psychiatry. 2003;34:129–140. [PubMed]

  • Carlbring P, Nilsson-Ihrfelt E, Waara J, et al. Treatment of panic disorder: live therapy vs. self-help via the internet.Behaviour Research and Therapy. 2005;43:1321–1333. [PubMed]

  • Carlbring P, Bohman S, Brunt S, et al. Remote treatment of panic disorder: a randomized trial of internet-based cognitive behavior therapy supplemented with telephone calls. American Journal of Psychiatry. 2006;163:2119–2125. [PubMed]

  • Carter RM, Wittchen H-U, Pfister H, et al. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depression and Anxiety. 2001;13:78–88. [PubMed]

  • Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. Journal of Clinical Psychiatry. 2004;65:7–12. [PubMed]

  • Christensen H, Griffiths K, Jorm A. Delivering interventions for depression by using the internet: randomised controlled trial. British Medical Journal. 2004;328:265. [PMC free article] [PubMed]

  • Clark DM, Layard R, Smithies R. Improving Access to Psychological Therapy: Initial Evaluation of the Two Demonstration Sites. London: Centre for Economic Performance, London School of Economics; 2008. CEP Discussion Papers, dp0897. [PMC free article] [PubMed]

  • Clark DM, Layard R, Smithies R, et al. Improving access to psychological therapy: initial evaluation of two UK demonstration sites. Behaviour Research and Therapy. 2009;47:910–920. [PMC free article] [PubMed]

  • Cloos J, Ferreira V. Current use of benzodiazepines in anxiety disorders. Current Opinion in Psychiatry. 2009;22:90–95. [PubMed]

  • Cochrane Collaboration. Review Manager (RevMan) version 5.0. Copenhagen: Nordic Cochrane Centre; 2008. [Computer programme]

  • Commander MJ, Odell SM, Surtees PG, et al. Care pathways for south Asian and white people with depressive and anxiety disorders in the community. Social Psychiatry and Psychiatric Epidemiology. 2004;39:259–264.[PubMed]

  • Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. American Journal of Psychiatry. 2004;161:414–425. [PubMed]

  • Cougle JR, Keough ME, Riccardi CJ, et al. Anxiety disorders and suicidality in the National Comorbidity Survey – replication. Journal of Psychiatric Research. 2009;43:825–829. [PubMed]

  • Craske MG, Rapee RM, Jackel L, et al. Qualitative dimensions of worry in DSM-III-R generalized anxiety disorder subjects and nonanxious controls. Behaviour Research and Therapy. 1989;27:397–402. [PubMed]

  • Crits-Christoph P, Connolly Gibbons MB, Narducci J, et al. Interpersonal problems and the outcome of interpersonally oriented psychodynamic treatment of GAD. Psychotherapy: Theory, Research, Practice, Training.2005;2:211–224.

  • Culpepper L. Generalized anxiety disorder and medical illness. Journal of Clinical Psychiatry. 2009;70(Suppl 2):20–24. [PubMed]

  • Curtis L. Unit Costs of Health and Social Care 2009. Canterbury: University of Kent; 2009.

  • Darcis T, Ferreri M, Natens J, et al. A multicentre double-blind placebo-controlled study investigating the anxiolytic efficacy of hydroxyzine in patients with generalized anxiety. Human Psychopharmacology: Clinical and Experimental. 1995;10:181–187.

  • Davidson JRT, DuPont RL, Hedges D, et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Journal of Clinical Psychiatry. 1999;60:528–535.[PubMed]

  • Davidson JRT, Bose A, Korotzer A, et al. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depression and Anxiety. 2004;19:234–240. [PubMed]

  • Davidson JRT, Wittchen H-U, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. European Neuropsychopharmacology.2008;18:673–681. [PubMed]

  • Davidson JR, Zhang W, Connor KM, et al. A psychopharmacological treatment algorithm for generalized anxiety disorder (GAD) Journal of Psychopharmacology. 2010;24:3–26. [PMC free article] [PubMed]

  • Davidson JRT, Feltner DE, Dugar A. Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs. Primary Care Companion Journal of Clinical Psychiatry. 2010;12:1–13. [PMC free article] [PubMed]

  • Davis M, Eshelman ER, McKay M. The Relaxation and Stress Reduction Workbook. 4th ed. Oakland, California: New Harbinger; 1995.

  • Davison G. Stepped care: doing more with less? Journal of Consulting and Clinical Psychology. 2000;68:580–585.[PubMed]

  • Deacon BJ, Abramowitz JS. Patients’ perceptions of pharmacological and cognitive-behavioural treatments for anxiety disorders. Behavior Therapy. 2005;36:139–145.

  • Decker ML, Turk CL, Hess B, et al. Emotion regulation among individuals classified with and without generalized anxiety disorder. Journal of Anxiety Disorders. 2008;22:485–494. [PubMed]

  • Dedovic K, Duchesne A, Andrews J, et al. The brain and the stress axis: the neural correlates of cortisol regulation in response to stress. NeuroImage. 2009;47:864–871. [PubMed]

  • Demyttenaere K, Jaspers L. Bupropion and SSI-induced side effects. Journal of Psychopharmacology. 2008;22:792–804. [PubMed]

  • DH. National Service Framework for Mental Health: Modern Standards and Service Models. 1999. [accessed June 2010]. Available from: http://www​.dh.gov.uk​/en/Publicationsandstatistics​/Publications​/PublicationsPolicyAndGuidance​/DH_4009598.

  • DH. NHS Reference Costs 2008–09. London: DH; 2010. [accessed May 2010]. Available from: http://www​.dh.gov.uk​/en/Publicationsandstatistics​/Publications​/PublicationsPolicyAndGuidance​/DH_111591.

  • Dhillon S, Yang LPH, Curran MP. Bupropion: a review of its use in the management of major depressive disorder.Drugs. 2008;68:653–689. [PubMed]

  • Diefenbach GJ, Stanley MA, Beck JG. Worry content reported by older adults with and without generalized anxiety disorder. Aging and Mental Health. 2001;5:269–274. [PubMed]

  • Diefenbach GJ, Carthy-Larzelere ME, Williamson DA, et al. Anxiety, depression, and the content of worries.Depression and Anxiety. 2001;14:247–250. [PubMed]

  • Dolan P. Modelling valuations for EuroQol health states. Medical Care. 1997;35:1095–1108. [PubMed]

  • Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population study. Health Economics. 1996;5:141–154. [PubMed]

  • Dugas MJ, Robichaud M. Description of generalized anxiety disorder. In: Dugas MJ, Robichaud M, editors.Cognitive-Behavioral Treatment for Generalized Anxiety Disorder: From Science to Practice. New York: Routledge; 2007. pp. 1–21.

  • Dugas M, Ladouceur R, Leger E, et al. Group cognitive-behavioral therapy for generalized anxiety disorder: treatment outcome and long-term follow-up. Journal of Consulting and Clinical Psychology. 2003;71:821–825.[PubMed]

  • Dugas MJ, Savard P, Gaudet A, et al. Can the components of a cognitive model predict the severity of generalized anxiety disorder? Behavior Therapy. 2007;38:169–178. [PMC free article] [PubMed]

  • Dugas MJ, Brillon P, Savard P, et al. A randomized clinical trial of cognitive-behavioral therapy and applied relaxation for adults with generalized anxiety disorder. Behavior Therapy. 2009;10:1–13. [PMC free article] [PubMed]

  • Duggan SE, Fuller MA. Duloxetine: a dual reuptake inhibitor. The Annals of Pharmacotherapy. 2004;38:2078–2085.[PubMed]

  • DuPont RL, Rice DP, Miller LS, et al. Economic costs of anxiety disorders. Anxiety. 1998;2:167–172. [PubMed]

  • Durham RC, Murphy T, Allan T, et al. Cognitive therapy, analytic psychotherapy and anxiety management training for generalized anxiety disorder. British Journal of Psychiatry. 1994;165:315–323. [PubMed]

  • Durham RC, Fisher PL, Dow MGT, et al. Cognitive behaviour therapy for good and poor prognosis generalized anxiety disorder. A clinical effectiveness study. Clinical Psychology and Psychotherapy. 2004;11:145–157.

  • Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: methods of developing guidelines for efficient drug use in primary care. British Medical Journal. 1998;316:1232–1235.[PMC free article] [PubMed]

  • Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs.1999;57:507–533. [PubMed]

  • Egan G. The Skilled Helper: A Systematic Approach to Effective Helping. Pacific Grove, California: Brooks/Cole; 1990.

  • Egger M, Juni P, Bartlett C, et al. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technology Assessment. 2003;7:1–76. [PubMed]

  • Engel K, Bandelow B, Gruber O, et al. Neuroimaging in anxiety disorders. Journal of Neural Transmission.2009;116:703–716. [PMC free article] [PubMed]

  • ESEMeD/MHEDEA 2000 Investigators. 12-month comorbidity patterns and associated factors in Europe: results from the European study of the epidemiology of mental disorders (ESEMeD) project. Acta Psychiatrica Scandinavica. 2004;109(Suppl. 420):28–37. [PubMed]

  • Ettigi P, Meyerhoff AS, Chirban JT, et al. The quality of life and employment in panic disorder. Journal of Nervous Mental Disorders. 1997;185:368–372. [PubMed]

  • Fanselow MS. Contextual fear, gestalt memories and the hippocampus. Behavioural Brain Research. 2000;110:73–81. [PubMed]

  • Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicentre study of pregabalin in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology. 2003;23:240–249. [PubMed]

  • Feltner D, Wittchen HU, Kavoussi R, et al. Long-term efficacy of pregabalin in generalized anxiety disorder.International Clinical Psychopharmacology. 2008;23:18–28. [PubMed]

  • Fenwick E, Klaxton K, Schulpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves.Health Economics. 2001;10:779–787. [PubMed]

  • Fresquet A, Sust M, Lloret A, et al. Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder.Annals of Pharmacotherapy. 2000;34:147–153. [PubMed]

  • Furukawa TA, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology. 2006;59:7–10. [PubMed]

  • Garner M, Mohler H, Stein DJ, et al. Research in anxiety disorders: from the bench to the bedside. European Neuropsychopharmacology. 2009;19:381–390. [PubMed]

  • Gelder M, Harrison P, Cowen P. Shorter Oxford Textbook of Psychiatry. London: Oxford University Press; 2006.

  • Gelenberg AJ, Lydiard B, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA: the Journal of the American Medical Association. 2000;283:3082–3088. [PubMed]

  • Gellatly J, Bower P, Hennessy S, et al. What makes self-help interventions effective in the management of depressive symptoms? Meta-analysis and meta-regression. Psychological Medicine. 2007;37:1217–1228. [PubMed]

  • Gilbody S, Bower P, Fletcher J, et al. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Archives of Internal Medicine. 2006;166:2314–2321. [PubMed]

  • Gili M, Comas A, Garcia-Garcia M, et al. Comorbidity between common mental disorders and chronic somatic diseases in primary care patients. General Hospital Psychiatry. 2010;32:240–245. [PubMed]

  • Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. Journal of Affective Disorders. 2005;87:161–167. [PubMed]

  • Goodwin RD, Faravelli C, Rosi S, et al. The epidemiology of panic disorder and agoraphobia in Europe. European Neuropsychopharmacology. 2005;15:435–443. [PubMed]

  • GRADE Working Group. Grading quality of evidence and strength of recommendations. British Medical Journal.2004;328:1490–1497. [PMC free article] [PubMed]

  • Grant BF, Hasin DS, Stinson FS, et al. The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry. 2004;67:363–374. [PubMed]

  • Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychological Medicine. 2005;35:1747–1759. [PubMed]

  • Gray JA. The Neuropsychology of Anxiety. London: Oxford University Press; 1982.

  • Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of anxiety disorders in the 1990s. Journal of Clinical Psychiatry. 1999;60:427–435. [PubMed]

  • Gregorian RS, Golden KA, Bahce A, et al. Antidepressant-induced sexual dysfunction. The Annals of Pharmacotherapy. 2002;36:1577–1589. [PubMed]

  • GSK. A randomized, double-blind, placebo-controlled, flexible dosage trial to evaluate the efficacy and tolerability of paroxetine CR in patients with generalised anxiety disorder (GAD) 2002 Unpublished.

  • GSK. Clinical evaluation of BRL29060A (paroxetine hydrochloride hydrate) in generalized anxiety disorder (GAD): a double-blind, placebo-controlled, comparative study. 2005 Unpublished.

  • Guest JF, Russ J, Lenox SA. Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom. European Journal of Health Economics. 2005;6:136–145.[PubMed]

  • Guizhen L, Yunjun Z, Linxiang G, et al. Comparative study on acupuncture combined with behavioral desensitization for treatment of anxiety neuroses. American Journal of Acupuncture. 1998;2–3:117–120.

  • Gum AM, Arean PA, Hunkeler E, et al. Depression treatment preferences in older primary care patients. The Gerontological Society of America. 2006;46:14–22. [PubMed]

  • Gunn J, Diggens J, Hegarty K, et al. A systematic review of complex system interventions designed to increase recovery from depression in primary care. BMC Health Services Research. 2006;6:88. [PMC free article] [PubMed]

  • Hackett D, Haudiquet V, Salinas E. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. European Psychiatry. 2003;18:182–187. [PubMed]

  • Hakkart-van Roijen L, van Straten A, Al M, et al. Cost-utility of brief psychological treatment for depression and anxiety. The British Journal of Psychiatry. 2006;188:323–329. [PubMed]

  • Hales RE, Hilty DA, Wise MG. A treatment algorithm for the management of anxiety in primary care practice.Journal of Clinical Psychiatry. 1997;59(Suppl. 3):76–80. [PubMed]

  • Halligan SL, Murray L, Martins C, et al. Maternal depression and psychiatric outcomes in adolescent offspring: a 13-year longitudinal study. Journal of Affective Disorders. 2007;97:145–154. [PubMed]

  • Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. American International Medicine. 2005;143:415–426. [PubMed]

  • Hanus M, Lafon J, Mathieu M. Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. Current Medical Research and Opinion. 2004;20:63–71.[PubMed]

  • Hartford J, Kornstein S, Liebowitz M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. International Clinical Psychopharmacology. 2007;22:167–174.[PubMed]

  • Haslam C, Brown S, Atkinson S, et al. Patients’ experiences of medication for anxiety and depression: effects on working life. Family Practice. 2004;21:204–212. [PubMed]

  • Hazlett-Stevens H, Craske MG, Roy-Byrne PP, et al. Predictors of willingness to consider medication and psychosocial treatment for panic disorder in primary care patients. General Hospital Psychiatry. 2002;24:316–321. [PubMed]

  • Healey M, Pickens R, Meish MD, et al. Effects of clorazepate, diazepam, lorazepam and placebo on human memory.Journal of Clinical Psychiatry. 1983;44:436–439. [PubMed]

  • Herrera-Arellano A, Jimenez-Ferrer E, Zamilpa A, et al. Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam. Planta Medica. 2007;73:713–717. [PubMed]

  • Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders.American Journal of Psychiatry. 2001;158:1568–1578. [PubMed]

  • Hettema JM, Prescott CA, Kendler KS. Genetic and environmental sources of covariation between generalized anxiety disorder and neuroticism. American Journal of Psychiatry. 2004;161:1581–1587. [PubMed]

  • Hettema JM, Prescott CA, Myers JM, et al. The structure of genetic and environmental risk factors for anxiety disorders in men and women. Archives of General Psychiatry. 2005;62:182–189. [PubMed]

  • Heuzenroeder L, Donnelly M, Haby MM, et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Australian and New Zealand Journal of Psychiatry. 2004;38:602–612. [PubMed]

  • Hewett K. A double-blind, placebo controlled study to evaluate the efficacy and tolerability of paroxetine in patients with generalised anxiety disorder (GAD) Unpublished. 2001

  • Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2. The Cochrane Collaboration; 2009. Available at www​.cochrane-handbook.org.

  • Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine. 2002;21:1539–1558. [PubMed]

  • Higgins JPT, Whitehead A. Borrowing strength from external trials in a meta-analysis. Statistics in Medicine.1996;15:2733–2749. [PubMed]

  • Houghton V. A quantitative study of the effectiveness of mindfulness-based stress reduction treatment, using an internet-delivered self-help program, for women with generalized anxiety disorder. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2008;69:3311.

  • Hoyer J, Becker ES, Margraf J. Generalized anxiety disorder and clinical worry episodes in a representative sample of young women. Psychological Medicine. 2002;32:1227–1237. [PubMed]

  • Hoyer J, Beesdo K, Gloster AT, et al. Worry exposure versus applied relaxation in the treatment of generalized anxiety disorder. Psychotherapy and Psychosomatics. 2009;78:106–115. [PubMed]

  • Hunot V, Churchill R, Silva de Lima M, et al. Psychological therapies for generalised anxiety disorder. Cochrane Database of Systematic Reviews. 2007;2007;(1):CD001848. [PubMed] [Cross Ref]

  • Hunt C, Issakidis C, Andrews G. DSM-IV Generalized anxiety disorder in the Australian National Survey of Mental Health and Well-Being. Psychological Medicine. 2002;32:649–659. [PubMed]

  • Iskedjian M, Walker JH, Bereza BG, et al. Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada. Current Medical Research and Opinion. 2008;24:1539–1548. [PubMed]

  • Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Controlled Clinical Trials. 1996;17:1–12. [PubMed]

  • Janbozorgi M, Zahirodin A, Norri N, et al. Providing emotional stability through relaxation training. Eastern Mediterranean Health Journal. 2009;15:629–638. [PubMed]

  • Johne A, Roots I. Clinical drug interactions with medicinal herbs. Evidence-Based Integrative Medicine. 2005;2:207–228.

  • Jørgensen TR, Stein DJ, Despiegel N, et al. Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. Annals of Pharmacotherapy. 2006;40:1752–1758. [PubMed]

  • Jorm AF, Christensen H, Griffiths KM, et al. Effectiveness of complimentary and self help treatments for anxiety disorders. Medical Journal of Australia. 2004;181:29–46. [PubMed]

  • Kadam UT, Croft P, McLeod J, et al. A qualitative study of patients’ views on anxiety and depression. British Journal of General Practice. 2001;51:375–380. [PMC free article] [PubMed]

  • Kahn E. Heinz Kohut and Carl Rogers: a timely comparison. American Psychologist. 1985;40:893–904.

  • Kaltenthaler E, Brazier J, De Nigris E, et al. Computerised Cognitive Behaviour Therapy for Depression and Anxiety Update: a Systematic Review and Economic Evaluation. Tunbridge Wells: Gray Publishing; 2006. Technical Report. [PubMed]

  • Kalueff AV, Nutt DJ. Role of GABA in anxiety and depression. Depression and Anxiety. 2007;24:495–517.[PubMed]

  • Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Services Research.1988;23:203–235. [PMC free article] [PubMed]

  • Kasper S, Herman B, Nivoli G, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. International Clinical Psychopharmacology.2009;24:87–96. [PubMed]

  • Kassinove H, Miller N, Kalin M. Effects of pre-treatment with rational emotive bibliotherapy and rational emotive audiotherapy on clients waiting at community mental health centre. Psychological Reports. 1980;46:851–857.[PubMed]

  • Kavoussi R. Pregabalin: from molecule to medicine. European Neuropsychopharmacology. 2006;16:S128–S133.[PubMed]

  • Keller MB. Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. Journal of Clinical Psychiatry. 2000;61:896–908. [PubMed]

  • Kenardy JA, Dow MGT, Johnston DW, et al. A comparison of delivery methods of cognitive-behavioural therapy for panic disorder: an international multicentre trial. Journal of Consulting and Clinical Psychology.2003;71:1068–1075. [PubMed]

    This is the primary reference for . Secondary references can be found in Appendix 15e.

  • Kendler KS. Major depression and generalised anxiety disorder. Same genes, (partly) different environments – revisited. British Journal of Psychiatry. 1996;30:68–75. [PubMed]

  • Kendler KS, Hettema JM, Butera F, et al. Life event dimensions of loss, humiliation, entrapment and danger in the prediction of onsets of major depression and generalized anxiety. Archives of General Psychiatry. 2003;60:789–796. [PubMed]

  • Kennedy BL, Schwab JJ. Utilization of medical specialists by anxiety disorder patients. Psychosomatics.1997;38:109–112. [PubMed]

  • Kessler RC. The epidemiology of pure and comorbid generalized anxiety disorder: a review and evaluation of recent research. Acta Psychiatrica Scandinavica. 2000;406(Suppl):S7–13. [PubMed]

  • Kessler RC, Wang PS. The descriptive epidemiology of commonly occurring mental disorders in the United States.Annual Review of Public Health. 2008;29:115–129. [PubMed]

  • Kessler RC, Brandenburg N, Lane M, et al. Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychological Medicine. 2005;35:1073–1078.[PubMed]

  • Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry. 2005;62:617–627. [PMC free article] [PubMed]

  • Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Archives of General Psychiatry. 2005;62:593–602. [PubMed]

  • Kessler RC, Chiu WT, Jin R, et al. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Archives of General Psychiatry. 2006;63:415–24. [PMC free article] [PubMed]

  • Kessler RC, Gruber M, Hettema JM, et al. Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. Psychological Medicine. 2008;38:365–374. [PMC free article] [PubMed]

  • Khan A, Brodhead AE, Kolts RL, et al. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. Journal of Psychiatric Research. 2005;39:145–150. [PubMed]

  • Kiropoulos LA, Klein B, Austin DW, et al. Is internet-based CBT for panic disorder and agoraphobia as effective as face-to-face CBT? Journal of Anxiety Disorders. 2008;22:1273–1284. [PubMed]

  • Kitchiner N, Edwards D, Wood S. A randomized controlled trial comparing an adult education class using cognitive behavioural therapy (‘stress control’), anxiety management group treatment and a waiting list for anxiety disorders. Journal of Mental Health. 2009;18:307–315.

  • Klein B, Richards JC, Austin DW. Efficacy of internet therapy for panic disorder. Journal of Behavioural Therapy.2006;37:213–238. [PubMed]

  • Klein B, Austin D, Pier C, et al. Frequency of email therapist contact and internet-based treatment for panic disorder: does it make a difference? Cognitive Behaviour Therapy. 2009;38:100–113. [PubMed]

  • Kolts RL, et al. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials.Journal of Psychiatric Research. 2005;39:145–150. [PubMed]

  • Koponen H, Allgulander C, Erickson J, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Primary Care Companion to the Journal of Clinical Psychiatry.2007;9:100–107. [PMC free article] [PubMed]

  • Kroenke K, Spitzer R, Williams JBW, et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity and detection. Annals of Internal Medicine. 2007;146:317–25. [PubMed]

  • Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology. 1998;139:402–406. [PubMed]

  • Ladouceur R, Dugas MJ, Freeston MH, et al. Efficacy of a cognitive-behavioral treatment for generalized anxiety disorder: evaluation in a controlled clinical trial. Journal of Consulting and Clinical Psychology. 2000;68:957–964. [PubMed]

  • Lang AJ. Mental health treatment preferences of primary care patients. Journal of Behavioral Medicine.2005;28:581–586. [PubMed]

  • Le Doux JE. Emotion circuits in the brain. Annual Review of Neuroscience. 2000;23:155–184. [PubMed]

  • Leichsenring F, Salzer S, Jaeger U, et al. Short-term psychodynamic psychotherapy and cognitive-behavioral therapy in generalized anxiety disorder: a randomized, controlled trial. American Journal of Psychiatry. 2009;166:875–881. [PubMed]

  • Lenox-Smith AJ, Reynolds A. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. British Journal of General Practice. 2003;53:772–777. [PMC free article] [PubMed]

  • Lenze EJ, Mulsant BH, Shear MK, et al. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. American Journal of Psychiatry.2005;162:146–150. [PubMed]

  • Lenze EJ, Rollman BL, Shear MK, et al. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA: the Journal of the American Medical Association. 2009;301:295–303. [PMC free article] [PubMed]

  • Liddel J, Williamson M, Irwig L. Method for Evaluating Research and Guideline Evidence. Sydney: New South Wales Health Department; 1996.

  • Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. European Neuropsychopharmacology. 2005;15:445–452. [PubMed]

  • Linden M, Zubraegel D, Baer T, et al. Efficacy of cognitive behaviour therapy in generalized anxiety disorders.Psychotherapy and Psychosomatics. 2005;74:36–42. [PubMed]

  • Llorca PM, Spadone C, Sol O, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. Journal of Clinical Psychiatry. 2002;63:1020–1027. [PubMed]

  • Lohoff FW, Etemad B, Mandos LA, et al. Ziprasidone treatment of refractory generalized anxiety disorder. Journal of Clinical Psychopharmacology. 2010;30:185–189. [PubMed]

  • Lovell K, Bee P. Implementing the NICE OCD/BDD guidelines. Psychology and Psychotherapy: Research and Practice. 2008;81:365–376. [PubMed]

  • Lovell K, Richards D. Multiple Access Points and Levels of Entry (MAPLE): ensuring choice, accessibility and equity for CBT services. Behavioural and Cognitive Psychotherapy. 2000;28:379–391.

  • Lovell K, Bower P, Richards D, et al. Developing guided self-help for depression using the Medical Research Council complex interventions framework: a description of the modelling phase and results of an explanatory randomised controlled trial. BMC Psychiatry. 2008;8:1–19. [PMC free article] [PubMed]

  • Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine.2004;23:3105–3124. [PubMed]

  • Lucock M, Padgett K, Noble R, et al. Controlled clinical trial of a self-help for anxiety intervention for patients waiting for psychological therapy. Behavioural and Cognitive Psychotherapy. 2008;36:541–551.

  • Lunn DJ, Thomas A, Best N, et al. WinBUGS – a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing. 2000;10:325–337.

  • Lydiard RB, Ballenger JC, Rickels K. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. The Journal of Clinical Psychiatry. 1997;58:11–18. [PubMed]

  • Machado M, Iskedjian M, Ruiz I, et al. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Current Medical Research and Opinion. 2006;22:1825–1837.[PubMed]

  • Majercsik E, Haller J, Leveleki C, et al. The effect of social factors on the anxiolytic efficacy of buspirone in male rats, male mice and men. Progress in Neuro-pharmacology and Biological Psychiatry. 2003;27:1187–1199.[PubMed]

  • Mann C, Staba EJ. The chemistry, pharmacology, and commercial formulations of chamomile. Journal of Herbs, Spices, Medicinal Plants. 1986;1:235–278.

  • Mann T. Clinical Guidelines: Using Clinical Guidelines to Improve Patient Care Within the NHS. London: NHS Executive; 1996.

  • Mantella RC, Butters MA, Amico JA, et al. Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinolgy. 2008;33:773–781. [PMC free article] [PubMed]

  • Marciniak M, Lage MJ, Landbloom RP, et al. Medical and productivity costs of anxiety disorders: case control study.Depression and Anxiety. 2004;19:112–120. [PubMed]

  • Marciniak MD, Lage MJ, Dunayevich E, et al. The cost of treating anxiety: the medical and demographic correlates that impact total medical costs. Depression and Anxiety. 2005;21:178–184. [PubMed]

  • Marks IM, Kenwright M, McDonough M, et al. Saving clinicians’ time by delegating routine aspects of therapy to a computer: a randomised controlled trial in phobia/panic disorder. Psychological Medicine. 2004;34:9–18.[PubMed]

  • Marrs R. A meta-analysis of bibliotherapy studies. American Journal of Community Psychology. 1995;23:843–870.[PubMed]

  • Maunder L, Cameron L, Moss M, et al. Effectiveness of self-help materials for anxiety adapted for use in prison: a pilot study. Journal of Mental Health. 2009;18:262–271.

  • McLeod DR, Hoehn-Saric R, Porges SW, et al. Effects of alprazolam and imipramine on parasympathetic cardiac control in patients with generalized anxiety disorder. Psychopharmacology. 1992;107:535–540. [PubMed]

  • McManus S, Meltzer H, Brugha T, et al. Adult Psychiatric Morbidity in England, 2007: Results of a Household Survey. Leeds: The NHS Information Centre for Health and Social Care; 2009.

  • MHRA. Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants. 2004. Available at: http://www​.MHRA.gov.uk​/home/groups/pl-p/documents​/drugsafetymessage/con019472​.pdf.

  • Michalopoulos C, Kiropoulos L, Shih STF, et al. Exploratory economic analyses of two primary care mental health projects: implications for sustainability. Medical Journal of Australia. 2005;183:S73–S76. [PubMed]

  • Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change. New York: Guilford; 2002.

  • Mohlman J, Gorenstein EE, Kleber M, et al. Standard and enhanced cognitive-behaviour therapy for late-life generalized anxiety disorder: two pilot investigations. American Journal of Geriatric Psychiatry. 2003;11:24–32.[PubMed]

  • Mojtabai R, Olfson M, Mechanic D. Perceived need and help-seeking in adults with mood, anxiety, or substance use disorders. Archives of General Psychiatry. 2002;59:77–84. [PubMed]

  • Moller H-J, Volz H-P, Reimann IW, et al. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam treated group. Journal of Clinical Psychopharmacology. 2001;21:59–65.[PubMed]

  • Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. Journal of Clinical Psychiatry. 2006;67:771–782. [PubMed]

  • Montgomery S, Chatamra K, Pauer L, et al. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. The British Journal of Psychiatry: the Journal of Mental Science. 2008;193:389–394. [PubMed]

  • Nadiga DN, Hensley PL, Uhlenhuth EH. Review of the long-term effectiveness of cognitive behavioral therapy compared to medications in panic disorder. Depression and Anxiety. 2003;17:58–64. [PubMed]

  • NCCMH. Depression: the Treatment and Management of Depression in Adults. Leicester & London: the British Psychological Society and the Royal College of Psychiatrists; 2010.

  • NCCMH. Depression in Adults with a Chronic Physical Health Problem: Treatment and Management. Leicester & London: the British Psychological Society and the Royal College of Psychiatrists; 2010.

  • NCCMH. Common Mental Health Disorders: Identification and Pathways to Care. Leicester & London: the British Psychological Society and the Royal College of Psychiatrists Forthcoming; 2011.

  • NHS, The Information Centre. Hospital Episode Statistics 2007–08. London: The NHS Information Centre; 2009. Available at: http://www​.hesonline.nhs.uk.

  • NICE. Clinical Guideline 22. London: NICE; 2004. Anxiety: Management of Anxiety (Panic Disorder, with or without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care. [PubMed]

  • NICE. Clinical Guideline 23. London: NICE; 2004. Depression: Management of Depression in Primary and Secondary Care.

  • NICE. Clinical Guideline 26. London: NICE; 2005. Post-traumatic Stress Disorder: The Management of PTSD in Adults and Children in Primary and Secondary Care. [PubMed]

  • NICE. Clinical Guideline 31. London: NICE; 2005. Obsessive-compulsive Disorder: Core Interventions in the Treatment of Obsessive-compulsive Disorder and Body Dysmorphic Disorder. [PubMed]

  • NICE. Technology Appraisal 97. London: NICE; 2006. Computerised Cognitive Behaviour Therapy for Depression and Anxiety.

  • NICE. Clinical Guideline 52. London: NICE; 2007. Drug Misuse: Opioid Detoxification.

  • NICE. Clinical Guideline 51. London: NICE; 2007. Drug Misuse: Psychosocial Interventions.

  • NICE. Guide to the Methods of Technology Appraisal. London: National Institute for Health and Clinical Excellence; 2008.

  • NICE. Social Value Judgements Principles for the Development of NICE Guidance. 2nd edition. London: NICE; 2008.

  • NICE. The Guidelines Manual. London: NICE; 2009.

  • NICE. Clinical Guideline 90. London: NICE; 2009. Depression: the Treatment and Management of Depression in Adults.

  • NICE. Clinical Guideline 91. London: NICE; 2009. Depression in Adults with a Chronic Physical Health Problem: Treatment and Management.

  • NICE. Clinical Guideline 100. London: NICE; 2010. Alcohol-Use Disorders: Diagnosis and Clinical Management of Alcohol-Related Physical Complications. [PubMed]

  • NICE. Public Health Guidance 24. London: NICE; 2010. Alcohol-Use Disorders: Preventing the Development of Hazardous and Harmful Drinking.

  • NICE. Clinical Guideline 115. London: NICE; 2011. Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence.

  • NICE. Common Mental Health Disorders: Identification and Pathways to Care. London: NICE Forthcoming; 2011.

  • Nicolini H, Bakish D, Duenas H, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychological Medicine. 2009;39:267–276. [PubMed]

  • Nimatoudis I, Zissis NP, Kogeorgos J, et al. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. International Clinical Psychopharmacology. 2004;19:331–336. [PubMed]

  • Nitschke JB, Sarinopoulos I, Oathes DJ, et al. Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. American Journal of Psychiatry.2009;166:302–310. [PMC free article] [PubMed]

  • Noyes J, Clarkson C, Crowe RR, et al. A family study of generalized anxiety disorder. American Journal of Psychiatry. 1987;144:1019–1024. [PubMed]

  • Olfson M, Gameroff MJ. Generalized anxiety disorder, somatic pain and health care costs. General Hospital Psychiatry. 2007;29:310–6. [PubMed]

  • ONS. Mid-2008 Population Estimates: England and Wales; Estimated Resident Population by Single Year of Age and Sex. London: Office for National Statistics; 2009. Available at: http://www​.statistics​.gov.uk/statbase/Product.asp?vlnk=15106.

  • Orsillo SM, Roemer L, Barlow DH. Integrating acceptance and mindfulness into existing cognitive-behavioral treatment for GAD: a case study. Cognitive and Behavioral Practice. 2003;10:222–230.

  • Öst LG. Applied relaxation: description of a coping technique and review of controlled studies. Behaviour Research and Therapy. 1987;25:397. [PubMed]

  • Öst LG, Breitholtz E. Applied relaxation versus cognitive therapy in the treatment of generalized anxiety disorder.Behaviour Research and Therapy. 2000;38:777–790. [PubMed]

  • Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial.American Journal of Psychiatry. 2003;160:533–540. [PubMed]

  • Pandina GJ, Canuso C, Turkoz, et al. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacology Bulletin. 2007;40:41–57.[PubMed]

  • Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends in Neurosciences. 2008;31:464–468. [PubMed]

  • Parker G, Hadzi-Pavlovic D, Greenwald S, et al. Low parental care as a risk factor to lifetime depression in a community sample. Journal of Affective Disorders. 1995;33:173–180. [PubMed]

  • Pfizer. European Assessment Report: LYRICA. London: European Medicines Agency; 2005.

  • Pfizer. A 4-week, double-blind, randomized, multicenter, fixed dose, placebo-controlled, parallel group study of lorazepam and paroxetine in patients with generalized anxiety disorder: Assessment of a new instrument intended to capture rapid onset. 2008 Unpublished.

  • Phillips ML, Drevets WC, Rauch SL, et al. Neurobiology of emotion perception I: the neural basis of normal emotion perception. Biological Psychiatry. 2003;54:504–514. [PubMed]

  • Pies R. Should psychiatrists use atypical antipsychotics to treat nonpsychotic anxiety. Psychiatry. 2009;6:29–37.[PMC free article] [PubMed]

  • Pohl RB, Feltner DE, Fieve RR, et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder. Double-blind, placebo-controlled comparison of BID versus TID dosing. Journal of Clinical Psychopharmacology. 2005;25:151–158. [PubMed]

  • Pollack M, Worthington J, Manfro G, et al. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. Journal of Clinical Psychiatry.1997;58:19–23. [PubMed]

  • Pollack MH, Zanelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry. 2001;62:350–357. [PubMed]

  • Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo-controlled study. Biological Psychiatry. 2006;59:211–215. [PubMed]

  • Porensky EK, Dew MA, Karp JF, et al. The burden of late-life generalized anxiety disorder: effects on disability, health-related quality of life, and healthcare utilization. American Journal of Geriatric Psychiatry. 2009;17:473–482. [PMC free article] [PubMed]

  • Prins MA, Verhaak PFM, Bensing JM, et al. Health beliefs and perceived need for mental health care of anxiety and depression: the patients’ perspective explored. Clinical Psychology Review. 2008;28:1038–1058. [PubMed]

  • Prins MA, Verhaak PFM, Meer KVD, et al. Primary care patients with anxiety and depression: need for care from the patient’s perspective. Journal of Affective Disorders. 2009;163:163–171. [PubMed]

  • Proudfoot J, Ryden C, Everitt B, et al. Clinical efficacy of computerised cognitive–behavioural therapy for anxiety and depression in primary care: randomised controlled trial. British Medical Journal. 2004;185:46–54. [PubMed]

  • Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. Journal of Clinical Psychiatry. 2004;65:1642–1653. [PubMed]

  • Reardon JM, Nathan NL. The specificity of cognitive vulnerabilities to emotional disorders: anxiety sensitivity, looming vulnerability and explanatory style. Journal of Anxiety Disorders. 2007;21:625–643. [PubMed]

  • Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. Journal of Affective Disorders. 1998;48:25–36. [PubMed]

  • Revicki DA, Brandenburg N, Matza L, et al. Health-related quality of life and utilities in primary-care patients with generalized anxiety disorder. Quality of Life Research. 2008;17:1285–94. [PubMed]

  • Rezvan S, Baghban I, Bahrami F, et al. A comparison of cognitive-behavior therapy with interpersonal and cognitive behavior therapy in the treatment of generalized anxiety disorder. Counselling Psychology Quarterly.2008;21:309–321.

  • Richards D, Richards A, Barkham M, et al. PHASE: a ‘health technology’ approach to psychological treatment in primary mental health care. Primary Health Care Research and Development. 2002;3:159–168.

  • Richards D, Lovell K, McEvoy P. Access and effectiveness in psychological therapies: self help as a routine health technology. Health and Social Care in the Community. 2003;11:175–182. [PubMed]

  • Richards DA, Weaver A, Utley M, et al. Developing evidence based and acceptable stepped care systems in mental health care: an operational research project. Final report. NIHR Service Delivery and Organisation programme; 2010. Available at: http://www​.sdo.nihr.ac​.uk/projdetails.php?ref=08-1504-109.

  • Richards J, Klein B, Austin D. Internet cognitive behavioural therapy for panic disorder: does the inclusion of stress management information improve end-state functioning? Clinical Psychologist. 2006;10:2–15.

  • Richardson R, Richards DA, Barkham M. Self-help books for people with depression: the role of the therapeutic relationship. Behavioural and Cognitive Psychotherapy. 2008;38:67–81. [PubMed]

  • Rickels K, Rynn MA. What is generalized anxiety disorder? Journal of Clinical Psychiatry. 2001;62(Suppl. 11):4–12.[PubMed]

  • Rickels K, Schweizer E. The clinical course and long-term management of generalized anxiety disorder. Journal of Clinical Psychopharmacology. 1990;10(Suppl. 3):101S–110S. [PubMed]

  • Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. American Journal of Psychiatry. 2000;157:968–974. [PubMed]

  • Rickels K, DeMartinis N, Aufdembrinke B. A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology. 2000;20:12–18.[PubMed]

  • Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. American Journal of Psychiatry. 2003;160:749–756. [PubMed]

  • Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder. A 4-week, multi-center, double-blind, placebo-controlled trial of pregabalin and alprazolam. Archives of General Psychiatry.2005;62:1022–1030. [PubMed]

  • Rijswijk EV, Hout HV, Lisdonk EVD, et al. Barriers in recognising, diagnosing and managing depressive and anxiety disorders as experienced by family physicians: a focus group study. BMC Family Practice. 2009;10[PMC free article] [PubMed] [Cross Ref]

  • Roemer L, Borkovec M, Posa S, et al. A self-report diagnostic measure of generalised anxiety disorder. Journal of Behavior Therapy and Experimental Psychiatry. 1995;26:345–350. [PubMed]

  • Roemer L, Molina S, Litz BT, et al. Preliminary investigation of the role of previous exposure to potentially traumatizing events in generalized anxiety disorder. Depression and Anxiety. 1996;4:134–138. [PubMed]

  • Roemer L, Molina S, Borkovec TD. An investigation of worry content among generally anxious individuals. Journal of Nervous and Mental Disease. 1997;185:314–319. [PubMed]

  • Roemer L, Orsillo SM, Salters-Pedneault K. Efficacy of an acceptance-based behavior therapy for generalized anxiety disorder: evaluation in a randomized controlled trial. Journal of Consulting and Clinical Psychology.2008;76:1083–1089. [PMC free article] [PubMed]

  • Rogers CR. The necessary and sufficient conditions of therapeutic personality change. Journal of Consulting Psychology. 1957;21:95–103. [PubMed]

  • Rogers CR. Rogers, Kohut and Erikson. A personal perspective on some similarities and differences. Person-Centered Review. 1986;1:125–140.

  • Rollman BL, Belnap BH, Mazumdar S, et al. A randomized trial to improve the quality of treatment for panic and generalized anxiety disorders in primary care. Archives of General Psychiatry. 2005;62:1332–1341. [PubMed]

  • Roth A, Fonagy P. What Works for Whom: A Critical Review of Psychotherapy Research. New York: Guilford; 1996.

  • Rowe SK, Rapaport MH. Classification and treatment of sub-threshold depression. Current Opinion in Psychiatry.2006;19:9–13. [PubMed]

  • Royal College of Psychiatrists. Council report CR59. London: Royal College of Psychiatrists; 2005. Benzodiazepines: Risks, Benefits, or Dependence A Re-evaluation.

  • Roy-Byrne PP, Wagner A. Primary care perspectives on generalized anxiety disorder. Journal of Clinical Psychiatry.2004;65(Suppl. 13):S20–26. [PubMed]

  • Roy-Byrne PP, Wagner AW, Schraufnagel TJ. Understanding and treating panic disorder in the primary care setting.Journal of Clinical Psychiatry. 2005;66(Suppl. 4):16–22. [PubMed]

  • Roy-Byrne PP, Davidson KW, Kessler RC, et al. Anxiety disorders and comorbid medical illness. General Hospital Psychiatry. 2008;30:208–225. [PubMed]

  • Roy-Byrne P, Craske MG, Sullivan G, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA: the Journal of the American Medical Association.2010;19:1921–1928. [PMC free article] [PubMed]

  • Ruan JIYU. Clinical observation on treatment of 86 patients with anxiety neurosis by combination of traditional herbs with acupuncture. Journal of Zhejiang College of TCM. 2003;27:70–71.

  • Rubin HC, Rapaport MH, Levine B, et al. Quality of well being in panic disorder: the assessment of psychiatric and general disability. Journal of Affective Disorders. 2000;57:217–221. [PubMed]

  • Ruscio AM, Borkovec TD. Experience and appraisal of worry among high worriers with and without generalized anxiety disorder. Behaviour Research and Therapy. 2004;42:1469–1482. [PubMed]

  • Ruscio AM, Chiu WT, Roy-Byrne P, et al. Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication. Journal of Anxiety Disorders. 2007;21:662–667. [PMC free article] [PubMed]

  • Rynn M, Russell J, Erickson J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depression and Anxiety. 2008;25:182–189. [PubMed]

  • Safren SA, Gershuny BS, Marzol P, et al. History of childhood abuse in panic disorder, social phobia and generalized anxiety disorder. Journal of Nervous and Mental Disease. 2002;190:453–456. [PubMed]

  • Sareen J, Jacobi F, Cox BJ, et al. Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Archives of Internal Medicine. 2006;166:2109–2116. [PubMed]

  • Schneider A, Mataix-Cols D, Marks I, et al. Internet-guided self-help with or without exposure therapy for phobic and panic disorders. Psychotherapy and Psychosomatics. 2005;74:154–164. [PubMed]

  • Schunemann HJ, Best D, Vist G, et al. for the GRADE Working Group. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. Canadian Medical Association Journal.2003;169:677–80. [PMC free article] [PubMed]

  • Schwartz TL, Nihalani N, Simionescu M, et al. History repeats itself: pharmacodynamic trends in the treatment of anxiety disorders. Current Pharmaceutical Design. 2005;11:255–263. [PubMed]

  • Scogin F, Hanson A, Welsh D. Self-administered treatment in stepped-care models of depression treatment. Journal of Clinical Psychology. 2003;59:341–349. [PubMed]

  • SIGN. SIGN 50: A Guideline Developer’s Handbook. Edinburgh: Scottish Intercollegiate Guidelines Network; 2001.

  • Silove D, Parker G, Hadzi-Pavlovic D, et al. Parental representations of patients with panic disorder and generalised anxiety disorder. British Journal of Psychiatry. 1991;159:835–841. [PubMed]

  • Simon G, Ormel J, von Korff M, et al. Health care costs associated with depressive and anxiety disorders in primary care. American Journal of Psychiatry. 1995;152:352–357. [PubMed]

  • Sorby NG, Reavley W, Huber JW. Self help programme for anxiety in general practice: controlled trial of an anxiety management booklet. British Journal of General Practice. 1991;41:417–420. [PMC free article] [PubMed]

  • Souêtre E, Lozet H, Cimarosti I, et al. Cost of anxiety disorders: impact of comorbidity. Journal of Psychosomatic Research. 1994;38(Suppl. 1):151–60. [PubMed]

  • Spek VRM, Cuijpers P, Nyklicek I, et al. Internet-based cognitive behaviour therapy for symptoms of depression and anxiety: a meta-analysis. Psychological Medicine. 2007;37:319–328. [PubMed]

  • Spiegelhalter DJ, Thomas A, Best NG, et al. WinBUGS User Manual: Version 14. Cambridge: MRC Biostatistics Unit; 2001.

  • Sramek J, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. Journal of Clinical Psychiatry. 1996;57:287–291. [PubMed]

  • Stanley MA, Beck JG, Glassco JD. Treatment of generalised anxiety in older adults: a preliminary comparison of cognitive-behavioral and supportive approaches. Behavior Therapy. 1996;27:565–581.

  • Stanley MA, Beck JG, Novy DM, et al. Cognitive-behavioral treatment of late-life generalised anxiety disorder.Journal of Consulting and Clinical Psychology. 2003;71:309–319. [PubMed]

  • Stanley MA, Wilson NL, Novy DM, et al. Cognitive behavior therapy for generalised anxiety disorder among older adults in primary care a randomized clinical trial. JAMA: the Journal of the American Medical Association.2009;301:1460–1467. [PMC free article] [PubMed]

  • Stein M, Sherbourne C, Craske M, et al. Quality of care for primary care patients with anxiety disorders. American Journal of Psychiatry. 2004;161:2230–37. [PubMed]

  • Stocchi F, Nordera G, Jokinen RH, et al. Efficacy and tolerability of paroxetine for the long term treatment of generalized anxiety disorder. Journal of Clinical Psychiatry. 2003;64:250–258. [PubMed]

  • Stone M, Laughren T, Jones M, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. British Medical Journal. 2009;339:b2880.[PMC free article] [PubMed]

  • Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Canadian Journal of Psychiatry. 2006;51:923–929. [PubMed]

  • Tarrier N, Main CJ. Applied relaxation training for generalised anxiety and panic attacks: the efficacy of a learnt coping strategy on subjective reports. British Journal of Psychiatry. 1986;149:330–336. [PubMed]

  • Tassone DM, Boyce E, Guyer J, et al. Pregabalin: a novel γ-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clinical Therapeutics. 2007;29:26–48. [PubMed]

  • Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatrica Scandinavica. 2008;118:434–442. [PubMed]

  • Titov N, Andrews G, Robinson E, et al. Clinician-assisted internet-based treatment is effective for generalized anxiety disorder: randomized controlled trial. Australian and New Zealand Journal of Psychiatry. 2009;43:905–912.

  • Truax CB, Carkhuff RR. Toward Effective Counseling and Psychotherapy: Training and Practice. Chicago, Illinois: Aldine; 1967.

  • Tylee A, Walters P. Underrecognition of anxiety and mood disorders in primary care: why does the problem exist and what can be done? Journal of Clinical Psychiatry. 2007;68:27–30. [PubMed]

  • Tyrer P, Baldwin DS. Generalised anxiety disorder. Lancet. 2006;368:2156–2166. [PubMed]

  • Tyrer P, Seivewright H, Johnson T. The Nottingham study of neurotic disorder: predictors of 12-year outcome of dysthymia, panic disorder and generalized anxiety disorder. Psychological Medicine. 2004;34:1385–1394.[PubMed]

  • Van Boeijen CA, van Oppen P, van Balkom A, et al. Treatment of anxiety disorders in primary care practice: a randomised controlled trial. British Journal of General Practice. 2005;55:763–769. [PMC free article] [PubMed]

  • Van Straten A, Tiemens B, Hakkaart L, et al. Stepped care vs. matched care for mood and anxiety disorders: a randomized trial in routine practice. Acta Psychiatrica Scandinavica. 2006;113:468–476. [PubMed]

  • Van Steenbergen-Weijenburg KM, van der Feltz-Cornelis CM, Horns EK, et al. Cost-effectiveness of collaborative care for the treatment of major depressive disorder in primary care. A systematic review. BMC Health Services Research. 2010;10:19. [PMC free article] [PubMed]

  • Vera-Llonch M, Dukes E, Rejas J, et al. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. European Journal of Health Economics.2010;11:35–44. [PMC free article] [PubMed]

  • Wade A, Rosenberg C. Citalopram in general practice: its efficacy and tolerability. International Journal of Psychiatry in Clinical Practice. 2001;7:123–128.

  • Wagner AW, Bystritsky A, Russo JE, et al. Beliefs about psychotropic medication and psychotherapy among primary care patients with anxiety disorders. Depression and Anxiety. 2005;21:99–105. [PubMed]

  • Ware JE, Snow KK, Kolinski M, et al. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Centre; 1993.

  • Ware JE, Kolinski M, Keller SD. How to Score the SF-12 Physical and Mental Health Summaries: a User’s Manual.Boston, MA: The Health Institute, New England Medical Centre; 1995.

  • Weinrieb RM, Auriacombe M, Lynch KG, et al. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. Journal of Clinical Psychiatry. 2003;64:1502–1510. [PubMed]

  • Weissman MM, Bland RC, Canino GJ, et al. The cross-national epidemiology of panic disorder. Archives of General Psychiatry. 1997;54:305–9. [PubMed]

  • Wells A. A metacognitive model and therapy for generalized anxiety disorder. Clinical Psychology and Psychotherapy. 1999;6:86–95.

  • Wells A. The metacognitive model of GAD: assessment of meta-worry and relationship with DSM-1V Generalized Anxiety Disorder. Cognitive Therapy and Research. 2005;29:107–121.

  • Wells A, Welford M, King P, et al. A pilot randomized trial of metacognitive therapy versus applied relaxation in the treatment of adults with generalised anxiety disorder. Behavior Research and Therapy. 2010;1:1–6. [PubMed]

  • Werneke U, Northey S, Bhugra D, et al. Antidepressants and sexual dysfunction. Acta Psychiatrica Scandinavica.2006;114:384–397. [PubMed]

  • Wernicke JF. Safety and side effect profile of fluoxetine. Expert Opinion on Drug Safety. 2004;3:495–504.[PubMed]

  • Wernicke J, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine. Drug Safety.2007;30:437–455. [PubMed]

  • Westra HA, Arkowitz H, Dozois DJA. Adding a motivational interviewing pre-treatment to cognitive behaviour therapy for generalized anxiety disorder. A preliminary randomized controlled trial. Journal of Anxiety Disorders.2009;23:1106–1117. [PMC free article] [PubMed]

  • Wetherell JL, Gatz M, Craske MG. Treatment of generalised anxiety disorder in older adults. Journal of Consulting and Clinical Psychology. 2003;71:31–40. [PubMed]

  • Wetherell JL, Kim DS, Lindamer LA, et al. Anxiety disorders in a public mental health system: clinical characteristics and service use patterns. Journal of Affective Disorders. 2007;104:179–83. [PMC free article] [PubMed]

  • White J. Stresspac: a controlled trial of a self-help package for the anxiety disorders. Behavioural and Cognitive Psychotherapy. 1995;23:89–107.

  • White J. ‘Stress control’ large group therapy for generalized anxiety disorder: two year follow up. Behavioural and Cognitive Psychotherapy. 1998;26:237–245.

  • White J, Keenan M, Brooks N. Stress control: a controlled comparative investigation of large group therapy for generalized anxiety disorder. Behavioural Psychotherapy. 1992;20:97–113.

  • WHO. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: WHO; 1992.

  • WHO. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research (ICD-10-DCR) Geneva, Switzerland: WHO; 1993.

  • Wittchen H-U. Generalized anxiety disorder: prevalence, burden and cost to society. Depression and Anxiety.2002;16:162–171. [PubMed]

  • Wittchen H-U, Essau CA. Epidemiology of panic disorder: progress and unresolved issues. Journal of Psychiatric Research. 1993;27(Suppl. 1):47–68. [PubMed]

  • Wittchen H-U, Jacobi F. Size and burden of mental disorders in Europe: a critical review and appraisal of 27 studies.European Neuropsycho-pharmacology. 2005;15:357–376. [PubMed]

  • Wittchen H-U, Carter R, Pfister H, et al. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. International Clinical Psychopharmacology. 2000;15:319–328. [PubMed]

  • Wittchen H-U, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. Journal of Clinical Psychiatry. 2002;63(Suppl. 8):24–34. [PubMed]

  • Wittchen H-U, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Archives of General Psychiatry. 1994;51:355–36. [PubMed]

  • Woelk H, Schlafke S. A multi-center, double-blind, randomised study of the lavender oil preparation silexan in comparison to lorazepam for generalized anxiety disorder. Phytomedicine. 2010;17:64–99. [PubMed]

  • Woelk H, Arnoldt KH, Kieser M, et al. Ginkgo biloba special extract EGb 761Reg. in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Research. 2007;41:472–480. [PubMed]

  • Yonkers KA, Warshaw MG, Massion AO, et al. Phenomenology and course of generalised anxiety disorder. British Journal of Psychiatry. 1996;168:308–313. [PubMed]

  • Yonkers KA, Dyck IR, Warshaw M, et al. Factors predicting the clinical course of generalised anxiety disorder.British Journal of Psychiatry. 2000;176:544–549. [PubMed]

  • Yuan Q, Li JN, Liu B, et al. Effect of Jin-3-needling therapy on plasma corticosteroid, adrenocorticotrophic hormone and platelet 5-HT levels in patients with generalized anxiety disorder. Chinese Journal of Integrative Medicine.2007;13:264–268. [PubMed]

  • Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? The American Journal of Medicine. 2006;119:719–727. [PubMed]

  • Zhang Y, Young D, Lee S, et al. Chinese Taoist cognitive psychotherapy in the treatment of generalised anxiety disorder in contemporary China. Transcultural Psychiatry. 2002;39:115–129.

  • Zhang H, Zeng Z, Deng H. Acupuncture treatment for 157 cases of anxiety neurosis. Journal of Traditional Chinese Medicine. 2003;23:55–56. [PubMed]

  • Zhao YH, Shan YH, Ma LH, et al. Clinical efficacy of hypnotherapy in the treatment of generalized anxiety disorder.Chinese Mental Health Journal. 2005;19:8.

  • Zhiling W, Yuhong L, Hong L, et al. Acupuncture treatment of generalized anxiety disorder. Journal of Traditional Chinese Medicine. 2006;26:170–171. [PubMed]

  • Zhou ZH, Yu WY, Wu ZH, et al. Clinical observations on treatment of anxiety neurosis with combined acupuncture and medicine. Shanghai Journal of Acupuncture and Moxibustion. 2003;22:9.

  • Zhu B, Zhao Z, Ye W, et al. The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder. Journal of Nervous and Mental Disease. 2009;197:136–139. [PubMed]